cendakimab (CC-93538) - AbbVie, BMS
Cendakimab: Data readout from P3 CC-93538-EE-001 trial (NCT04753697) for eosinophilic esophagitis in 2024 (Bristol-Myers Squibb) - Feb 2, 2024 - Q4 2023 Results 
P3 data • Eosinophilic Esophagitis • Immunology
https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2023/BMY-2023-Q4-Results-Investor-Presentation-with-Appendix.pdf
 
Feb 2, 2024
 
 
3613cee6-0314-4a39-8e94-e743fe3f7195.png